Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial).

Frontiers in oncology·2026

Same author

Development of potent BChE/Nrf2 modulators for Alzheimer's disease treatment via dual suppression of ferroptosis.

European journal of medicinal chemistry·2026

Same author

Exploring the molecular classification-based personalized treatment decision-making in FIGO stage I-III endometrial carcinoma after surgery: a population-based real-world study.

Therapeutic advances in medical oncology·2026

Same author

A unified spatial transcriptome profiling of ten mouse organs.

Scientific data·2026

Same author

Colloids in lubrication: Development of amphiphiles from molecular structure to tribological performance.

Advances in colloid and interface science·2026

Same author

AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes.

Science bulletin·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

PAM50 Intrinsic Subtypes and Immunity Status in Prognosis of Triple-Negative Breast Cancer: A Retrospective Cohort

Yuan Wang¹, Yu Song², Songjie Shen²

¹Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

|December 30, 2025

Summary

This summary is machine-generated.

Triple-negative breast cancer (TNBC) prognosis varies despite chemotherapy. Molecular subtypes and immune status significantly impact patient outcomes, offering new insights for adjuvant treatment decisions in TNBC.

Keywords:

PAM50 intrinsic subtype PD-L1 expression level adjuvant chemotherapy immunity score triple negative breast cancer

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Jun 19, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Molecular Biology
Immunology

Background:

Triple-negative breast cancer (TNBC) exhibits variable prognoses despite standard adjuvant chemotherapy.
Understanding TNBC heterogeneity, including molecular subtypes and immune microenvironment, is crucial for personalized treatment.

Purpose of the Study:

To investigate the prognostic impact of intrinsic molecular subtypes and immune status in TNBC patients receiving adjuvant chemotherapy.
To correlate multigene profiling with clinical outcomes and immune markers for improved risk stratification.

Main Methods:

Retrospective analysis of 111 TNBC patients treated with surgery and adjuvant chemotherapy.
PAM50 gene expression profiling for intrinsic subtype classification (luminal A, luminal B, HER2-enriched, basal-like).
Assessment of recurrence-of-risk (ROR) scores and immune status (17-gene panel) correlating with clinical outcomes (DFS, OS) and immune markers (TILs, PD-L1).

Main Results:

Basal-like subtype was the most prevalent (77%).
Luminal A subtype with low-to-intermediate ROR scores showed poorer outcomes, while high-ROR patients had the longest disease-free survival (DFS).
Immune-strong status significantly correlated with improved DFS and overall survival (OS) in stage IIB-III patients, associated with higher TILs and PD-L1 expression.

Conclusions:

Multigene assessment of molecular subtype and immune status provides critical prognostic information for TNBC patients.
These factors may guide adjuvant treatment decisions, especially for non-basal-like TNBC subtypes.
Immune status is a significant prognostic indicator in specific TNBC stages.